Adjuvant chemotherapy and trastuzumab is safe and effective in older women with small, node-negative, HER2-positive early-stage breast cancer Journal Article

   

Authors:	Cadoo, K. A.; Morris, P. G.; Cowell, E. P.; Patil, S.; Hudis, C. A.; McArthur, H. L.
Article Title:	Adjuvant chemotherapy and trastuzumab is safe and effective in older women with small, node-negative, HER2-positive early-stage breast cancer
Abstract:	Micro-Abstract The benefit of adjuvant trastuzumab with chemotherapy in breast cancer is well-established; however, its impact on outcomes for older women with small, node-negative, human epidermal growth factor receptor 2-positive disease is less clear and unlikely to be addressed in prospective studies. This retrospective, sequential cohort study suggests adjuvant trastuzumab with chemotherapy results in excellent breast cancer outcomes with few cardiac events in this population. © 2016 Elsevier Inc.
Keywords:	chemotherapy; breast cancer; trastuzumab; her2 positive; cardiac outcomes
Journal Title:	Clinical Breast Cancer
Volume:	16
Issue:	6
ISSN:	1526-8209
Publisher:	Elsevier Inc.
Date Published:	2016-12-01
Start Page:	487
End Page:	493
Language:	English
DOI:	10.1016/j.clbc.2016.07.013
PROVIDER:	scopus
PUBMED:	27622751
PMCID:	PMC5575753
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-84995475211&partnerID=40&md5=709a83980d877949d48e51ed46656b2e
Notes:	Article -- Export Date: 6 December 2016 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/101278